US Food and Drug Administration Approval Summary: Fam-Trastuzumab Deruxtecan-nxki for Human Epidermal Growth Factor Receptor 2-Low Unresectable or Metastatic Breast Cancer
Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial
MARGITUXIMAB vs TRASTUZUMAB in pazienti con carcinoma mammario HER2-positivo avanzato pretrattato: risultati dello studio randomizzato di fase III SOPHIA
